Curaleaf Holdings, Inc. reports developments across its consumer cannabis business, including retail dispensary openings, medical and adult-use product brands, quarterly operating results, and international expansion. The company trades on the Toronto Stock Exchange as CURA and on OTCQX as CURLF.
Recurring updates cover brands such as Curaleaf, Select, Grassroots, Find, Dark Heart, Anthem, and Four 20 Pharma; U.S. dispensary activity; medical cannabis distribution in Germany and other international markets; share repurchase activity; board and shareholder matters; and regulatory topics affecting cannabis operations.
Curaleaf (CURLF) has filed an update increasing its offer to acquire all outstanding Aurora Cannabis common shares for implied consideration of US$5.00 per share. Aurora shareholders would receive 0.4013 Curaleaf subordinate voting shares plus US$1.00 cash per share. The implied value uses Curaleaf's October 2, 2026 closing price of C$14.21 and an exchange rate of C$1.00 to US$0.7015.
The enhanced offer represents an 86% premium to Aurora's US$2.75 30-day volume-weighted average price as of August 10, 2026. The maximum consideration would rise from US$5.00 to US$6.00 per Aurora share, representing a 118% premium to that reference price. Curaleaf filed the update with Canadian securities authorities and a new Form F-80 registration statement with the U.S. Securities and Exchange Commission. The acquisition remains an offer, not a completed transaction.
Curaleaf (CURLF) plans to enhance its offer to acquire all outstanding Aurora Cannabis common shares to US$5.00 per share in implied consideration. The proposed terms comprise 0.4013 Curaleaf shares plus US$1.00 cash per Aurora share, based on Curaleaf's October 2, 2026 closing share price and the stated exchange rate. Total implied consideration rises 25%, cash consideration rises 33%, and the maximum consideration increases 20% to US$6.00 per Aurora share.
Curaleaf expects to extend the offer deadline to 11:59pm Mountain Time on December 4, 2026. The proposal was developed solely from public information, with formal due diligence still sought. The proposed combination would have more than US$1.5 billion in last-twelve-month revenue, nearly US$350 million in adjusted EBITDA, an earnings measure, and at least US$40 million in expected annual cost savings.
Curaleaf (CURLF) is running its seventh annual Breast Cancer Action Month checkout donation campaign from October 1 through October 31, 2026. Proceeds benefit Impact One Breast Cancer Foundation. Curaleaf and its customers have donated more than $600,000 combined since 2020, including over $75,000 raised last year. Customers can round up purchases or donate $1 or $5 in all Curaleaf states except Ohio, where regulations prohibit round-up campaigns.
Curaleaf (CURLF) plans to report third-quarter 2026 financial and operating results after market close on November 3, 2026. Management will host a conference call and audio webcast at 5:00 p.m. ET that day, with prepared remarks followed by a question-and-answer session.
Summary not available.
Curaleaf (CURLF) has been added to the FTSE Canada All Cap Index, effective after the close of trading on September 18, 2026.
This is Curaleaf’s second inclusion in a major Canadian benchmark, following its September 2025 addition to the S&P/TSX Composite Index under the Health Care sector. The company said that each index addition exposes its shares to new passive and active institutional funds, which it views as supporting greater liquidity, a broader shareholder base, and increased investor attention on U.S. cannabis.
Curaleaf (CURLF) is relocating its Hartford, Connecticut dispensary to a new store in Meriden, Connecticut, which is set to open on Friday, September 18.
The new Curaleaf Meriden location at 443 S Broad St. keeps the company’s footprint at four stores in Connecticut and 179 locations nationwide. Situated in a commercial district in New Haven County between Hartford and New Haven, the store is intended to improve access for local and regional patients and consumers. It will offer a broad range of cannabis products, including Dark Heart ultra-premium flower, FIND flower, Grassroots, Jams Edibles, and Select Briq 2 all-in-one vapes.
Curaleaf (CURLF) is relocating its Passyunk, Pennsylvania medical cannabis dispensary to a larger site in Philadelphia’s Fishtown neighborhood, opening to patients on September 17 at 1321 N. Front St. The move preserves Curaleaf’s total of 18 dispensaries in Pennsylvania and 179 locations nationwide, while offering expanded retail space, broader product selection and a redesigned shopping experience. The Fishtown site features a custom mural by local artists VURT Creative and stocks Curaleaf brands such as Grassroots, FIND, Select, Dark Heart, and the Select Briq 2 all‑in‑one vape device. Regular hours run Monday–Saturday 9:00 a.m.–8:00 p.m. and Sunday 9:00 a.m.–7:00 p.m., with a grand opening event on September 23.
Curaleaf Holdings (CURLF) is opening its Curaleaf Port Richey dispensary in Florida on September 17, 2026, expanding its retail footprint.
The new location at 8605 US Hwy 19 in Port Richey increases Curaleaf’s Florida dispensary count to 78 and its nationwide total to 179 stores. Situated in a busy retail corridor in the Tampa area near Historic Downtown New Port Richey and Sims Park, the dispensary will serve medical cannabis patients with a range of products, including Florida‑exclusive Reef flower, Dark Heart ultra‑premium flower, FIND flower, Anthem pre‑rolls and the Select Briq 2 all‑in‑one vape. Grand opening celebrations are scheduled for September 25 and 26 with brand activations, promotions and giveaways.
Curaleaf (CURLF) is urging Aurora Cannabis shareholders to accept its tender offer, which represents a stated 45% premium to Aurora’s 30‑day VWAP as of August 10, 2026.
The offer consists of 0.3463 Curaleaf shares plus US$0.75 in cash per Aurora share, implying an offer price of US$4.00 based on the unaffected price, or about US$75 in cash and approximately 35 Curaleaf shares for every 100 Aurora shares. Curaleaf projects the combined company would have operations in 17 countries, more than US$1.5 billion in last‑twelve‑month revenue and nearly US$350 million in adjusted EBITDA, with at least US$40 million in expected annual cost synergies. Aurora shareholders must tender their shares by December 1, 2026 to participate, and Curaleaf has scheduled a live shareholder Q&A with its chairman and CEO Boris Jordan on September 17 at 10:30 a.m. ET.